CompletedNot Applicable

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

France300 participantsStarted 2020-01-07

Plain-language summary

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material. The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: \- Healthcare professionals who are current or past prescribers of Dengvaxia Exclusion criteria: * Healthcare professionals who have never prescribed Dengvaxia * Healthcare professionals who may have a conflict of interest with the survey (i.e. Healthcare professionals employed by regulatory bodies, pharmaceutical industries) * Healthcare professionales who have participated in testing the questionnaire for comprehensibility, consistency and the appropriateness of medical terms The above information is not intended to contain all considerations relevant to participation in the survey.

What they're measuring

Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materials

Timeframe: Day 0

Trial details

NCT IDNCT04170140

SponsorSanofi Pasteur, a Sanofi Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-03-05

View on ClinicalTrials.gov More Dengue Virus Infection trials